The headline news from the American Patients First blueprint is that Trump hasn't followed through on earlier promises to have the federal government negotiate the price of drugs used in the Medicare system, and hasn't made it possible for United States citizens to import lower-cost medicines from overseas.
In his remarks, Azar outlined a presidential directive to "bring negotiation where it doesn't exist", merging Part B, Medicare's program for physician-administered drugs, with Part D. The Part D program was implemented in 2006 - when Azar was deputy health secretary and before he departed to become president of Eli Lilly's USA subsidiary.
Medicare negotiating drug prices directly could result in significant savings. Trump promised to take on the "tangled web of special interests" that drive up drug prices, noting the high amount that pharma companies spend on lobbyists to "protect the status quo" and "keep drug prices high".
He said the reforms will take some time, but the administration will look to Congress for help in some of these new measures.
We will have tougher negotiation, more competition and much lower prices at the pharmacy counter. He blasted drug makers, health insurers, pharmacy benefit managers and others for profiting off American patients.
Instead, a main initiative unveiled by Trump on May 11 was proposed to compel other industrial nations to pay more for innovative medicines, particularly Canada, Japan, and some European countries. "We believe Americans should know which drug companies are gouging consumers and which ones are being good actors for our communities". And the HHS secretary wants to get rid of "gag rules" that limit how pharmacists can steer customers to less costly products, and to require doctors to disclose out-of-pocket costs for drugs they prescribe for patients. This also gives manufactures the incentive to raise prices and gives providers the incentive to select more expensive medicines. But there are big, they are bold steps.
82 women walk Cannes red carpet in protest
It preceded a gala premiere for " Girls of the Sun ", a Kurdish female freedom-fighters drama from director Eva Husson. Jane Campion is the only female director to have won the Palme d'Or, for her 1993 film "The Piano".
Vodacom adds 4.5m customers in South Africa
The addition of the Kenyan company helped Vodacom increase net profit by almost 19 percent to R15.6-billion. It announced a final dividend of 425 cents per share, down from 435 cents a year ago .
North West becomes first province taken over by national government
A minister involved in the process reportedly told Daily Maverick that the province was placed under administration partly to cut off money flows to Mahumapelo.
Currently, any medications a manufacturer includes in the federal Medicaid drug rebate program are automatically on the formulary.
Shares of Indian drug makers, who derive large part of their sales from US, gained on Monday - more in relief - as US President Donald Trump's speech on drug pricing eventually turned out to be more rhetorical than substantive.
At a press briefing in Washington D.C., Health and Human Services Secretary Alex Azar said that since Trump took office in January 2017, the Food and Drug Administration "has approved more generic drugs than ever before in history, saving $8.8 billion in the first year". Democrats also want more transparent calculation of the "true cost" of drug production as a basis for pricing, and they urge an end to tactics created to extend patent protections, such as pay-for-delay deals, patent "evergreening", and the use of FDA Risk Evaluation and Mitigation Strategies (REMS) to block competition.
Their joint report, titled, Sudden Price Spikes in Off-Patent Prescription Drugs:The Monopoly Business Model that Harms Patients, Taxpayers, and the U.S. Health Care System, uncovered a business model that holds patients hostage in order to boost the bottom line for pharmaceutical companies.
Health policy experts, however, have questioned whether the administration's proposals to date will have a meaningful impact on the high cost of prescriptions.